Events Hosted by NEWDIGS (attendance by Invitation)

July 9, 2014 Cambridge, MA, “The Next Act: What’s Needed to Make Orphan Drugs Readily Available to People with Rare Diseases.” Co-hosted by NORD and MIT LFE.
June 4-5, 2014 Cambridge, MA, NEWDIGS Quarterly Workshop
April 2-3, 2014 London, “Global Updates on Accelerated Access to Innovative Medicines for Patients in Need,” Workshop Co-hosted by EMA, IMI, EFPIA, & MIT NEWDIGS.

Events and Presentations

August 25, 2014
Boston, Tufts Center for the Study of Drug Development, in partnership with the Manhattan Institute’s Project FDA. Building a 21st Century Health Care System: Aligning Policy, Accelerating Cures, Delivering Hope. Panel: “Using Big Data to Support Patient-Centered Innovation.” Gigi Hirsch (MIT).
June 15-19, 2014 San Diego, DIA 2014. (1) “Adaptive, Progressive or Risk-Based Licensing Models: What Approaches Could Be Considered by Mature and Emerging Markets?” Panel Moderator: Lawrence Liberti (CISR). Hans-Georg Eichler (EMA) – An Update on International Developments. (2) “How Can Studies that Inform Relative Effectiveness Best Be Incorporated into Global Drug Development Plans?” Panel Moderator: Chris Chinn (GSK). Mark Trusheim (MIT) – Overview of the NEWDIGS Janus Initiative.
June 13, 2014
Boston, Global Clinical Scholars Training Program @ Harvard Medical School. “Overview of NEWDIGS & Adaptive Licensing,” Gigi Hirsch (MIT).
May 8, 2014 Washington DC, NORD Corporate Council Meeting. “Overview of NEWDIGS-Adaptive Licensing,” Thomas Unger (Pfizer).
March 26, 2014 Vienna, DIA EuroMeeting 2014. “Creating an Adaptive Pathway for Medicines to Patients–Could this Be An Approach That Fulfills the Needs of All Decision-Makers? A Roundtable Discussion.” Moderator: Andrzej Rys (European Commission, Belgium); Hans-Georg Eichler (EMA); Jurgen Windeler (IQWiG, Germany); Tomas Salmonson (CHMP/EMA); Carole Longson (NICE); Chris James (Motor Neurone Disease Association, United Kingdom); Anton Hoos (GSK).
February 13-14, 2014 San Francisco, 21st International Molecular Medicine Tri-Conference, Leaders in Precision Medicine Symposium. “Adaptive Licensing as an Enabler for Precision Medicine,” Panel: Hans-Georg Eichler (EMA), Kenneth Oye (MIT), Ed Pezalla (Aetna), Mark Trusheim (MIT), & Thomas Unger (Pfizer).
February 10, 2014 Washington DC, DIA 2014. (1) “Adaptive Licensing and Benefit-Risk,” John Ferguson (Novartis). (2) “Benefit-Risk Assessment from Inception to Maturity: Aligning Regulatory and Industry Goals,” Panelists: Hans-Georg Eichler (EMA) and Robyn Lim (Health Canada).
February 3-6, 2014 Washington DC, HTAi Forum. Origins and Current Thinking on Adaptive Pathways. Hans-Georg Eichler (EMA)

2013 Events
2012 Events
2011 Events
2010 Events